In Brief
Refine Search
Biotechnology
The US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab), Merck & Co’s mega-blockbuster anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the treatment of patients with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer. 13 January 2024
Biotechnology
Outlining its goal of five launches over five years to 2028, Vertex Pharmaceuticals chief executive Reshma Kewalramani has presented a corporate update at the JP Morgan Healthcare Conference. 10 January 2024
Biotechnology
Sarepta Therapeutics has provided a corporate update and outlined clinical and commercial progress at the 2024 JP Morgan Healthcare Conference. 10 January 2024
Biotechnology
Gilead Sciences is looking ahead to a “clinical pipeline full of catalysts in 2024,” according to a presentation given to investors at the JP Morgan Healthcare Conference in California. 9 January 2024
Biotechnology
At the JP Morgan Health Conference, Swiss cancer giant Novartis has presented a corporate update, highlighting clinical and commercial progress while outlining its future strategy. 9 January 2024
Biotechnology
Japan’s Eisai and US biotech Biogen announced that their humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab-irmb) has been approved in China as a treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia. 9 January 2024
Pharmaceutical
California’s Revagenix has closed a series B funding round from core investors Tenmile and Novo Holdings, raising an undisclosed sum. 8 January 2024
Pharmaceutical
Turbine AI, a UK-based biological simulation company building a platform for interpreting human biology in silico, has entered into a collaboration with British pharma major AstraZeneca. 6 January 2024
Biotechnology
A new genomic medicine start-up, Moonwalk Biosciences, has launched in California with $57 million in seed and series A financing. 5 January 2024
Pharmaceutical
Denmark’s Union Therapeutics has said that its chief executive, Kim Kjøller, will be making a presentation at the JP Morgan Healthcare Conference on January 8. 5 January 2024
Biotechnology
German family-owned pharma major Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen discovery platform, EDAPT. 4 January 2024
Biotechnology
US biotech Arrowhead Pharmaceuticals today announced the pricing of an underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share, offered at a price of $28.50 per share, before underwriting discounts. 3 January 2024
Pharmaceutical
The British business of Italian drugmaker Menarini has been granted marketing authorization for Korserdu (elacestrant) in the UK. 3 January 2024
Biotechnology
US biotech Mersana Therapeutics and Germany’s Merck KGaA have mutually agreed to terminate both the collaboration and commercial license agreement of June 2014 on Dolaflexin between the parties 2 January 2024
Biotechnology
Drug resistance specialist InMed has inked a deal with fellow Chinese firm Escugen, a clinical-stage antibody–drug conjugate (ADC) developer. 2 January 2024
Biotechnology
Shanghai Henlius Biotech has announced that PT Kalbio Global Medika, the subsidiary of Henlius' partner PT Kalbe Genexine Biologics (KGbio), has received the relevant registration certificates issued by Indonesia’s National Agency for Drug and Food Control for the approval of Henlius’ self-developed and manufactured anti-PD-1 monoclonal antibody (MAb) Hansizhuang (serplulimab) in Indonesia under the trade name Zerpidio for the treatment of extensive stage small cell lung cancer (ES-SCLC). 29 December 2023
Biotechnology
A licensing agreement between vTv Therapeutics and Huadong Pharmaceutical will be scrapped, after the latter stated its intent to withdraw from the deal, a filing with the US SEC reveals. 28 December 2023
Pharmaceutical
Swedish biotech Calliditas Therapeutics has announced that it has refinanced its debt to the tune of $102 million, shortly after Tarpeyo (budesonide) received regular approval in the USA. 28 December 2023
Biotechnology
A licensing agreement has been reached between Suzhou-based Ribo Life Science and Jinan-headquartered Qilu Pharmaceutical. 27 December 2023
Biotechnology
Shares of Theseus Pharmaceuticals rose 7% to $3.96 pre-market, on the news that it has received a takeover bid from Concentra Biosciences, in an all-cash deal worth at least $172.5 million. 22 December 2023
Biotechnology
Dutch gene therapy company uniQure (Nasdaq: QURE) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to AMT-130, sending the firm’s shares leaping more than 38% to $13.00 by close of trading on Thursday. 18 April 2025
Pharmaceutical
US President Donald Trump issued an executive order on April 15 listing several potential policy changes aimed at lowering US drug prices.
Responding to the announcement, Morningstar’s healthcare equity research director Karen Andersen gave her views on why this matters. 18 April 2025
Biotechnology
The US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) Injection 8mg, submitted by US biotech Regeneron Pharmaceuticals. 18 April 2025
Biotechnology
Australian clinical-stage biotech Neurizon Therapeutics, which is advancing innovative treatments for neurodegenerative diseases, has significantly strengthened its executive management team with three key appointments. 18 April 2025
Pharmaceutical
US biopharma company Galmed Pharmaceuticals has entered into a research collaboration with Virginia Commonwealth University to investigate its lead candidate Aramchol (arachidyl amido cholanoic acid) as a potential solution to drug resistance in gastrointestinal cancers. 17 April 2025
Biotechnology
BigHat Biosciences, a Californian biotech with a machine learning (ML)-guided antibody discovery and development platform, has announced a strategic collaboration with US pharma major Eli Lilly. 17 April 2025
Biotechnology
US cancer drug developer Werewolf Therapeutics today announced the appointment of Steven Bloom as chief business officer (CBOP. 17 April 2025
Pharmaceutical
Wall Street watched in awe as Eli Lilly made rampant gains in early trading Thursday. 17 April 2025
Biotechnology
Swiss pharma major Novartis has discontinued development of its experimental treatment QUC398 for knee osteoarthritis, ending hopes for a new therapy in the anti-ADAMTS-5 class. 17 April 2025
Pharmaceutical
Florida biopharma Ligand Pharmaceuticals subsidiary Pelthos Therapeutics is to merge with Channel Therapeutics, a developer of non-opioid pain treatments. 17 April 2025
Pharmaceutical
India’s Venus Remedies has secured Qualified Infectious Disease Product designation from the United States Food and Drug Administration for its investigational antibiotic VRP-034, a next-generation formulation of polymyxin B designed to reduce kidney toxicity. 17 April 2025
Biosimilars
Indian drugmaker Biocon subsidiary Biocon Biologics has announced a settlement and license agreement with the USA’s Regeneron that clears the way to commercialize Yesafili (aflibercept-jbvf), an interchangeable biosimilar aflibercept, in the USA. 17 April 2025
Biotechnology
Germany’s Evotec has unveiled a new strategy, and provided 2025 guidance—bolstered by strong results from the fourth-quarter of 2024. 17 April 2025
Biotechnology
Japanese drugmaker Chugai Pharmaceutical announced that results from the Phase III clinical trial (NIHONBASHI study) of anti-VEGF/anti-Ang-2 bispecific antibody Vabysmo (faricimab) intravitreal injection 120mg/mL, for angioid streaks associated with neovascularization were presented at the 129th Annual Meeting of the Japanese Ophthalmological Society on April 17. 17 April 2025
Pharmaceutical
Switzerland-based Addex Therapeutics, a biopharma developing a portfolio of novel small molecule allosteric modulators for neurological disorders, has announced an update on its Phase II asset, ADX71149. 17 April 2025
Biotechnology
US gene therapy company bluebird bio announced that after three weeks of engagement, including a timeline extension, Ayrmid Pharma has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. 17 April 2025
Pharmaceutical
The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). 17 April 2025
Pharmaceutical
US biotech Wayfinder Biosciences has entered a research collaboration with Japanese drugmaker Daiichi Sankyo to develop small molecule therapies targeting RNA in neurodegenerative diseases. 16 April 2025
Biosimilars
China’s Chime Biologics has formed a strategic partnership with European biosimilars specialist Polpharma Biologics to support the end-to-end development and manufacture of a biosimilar product targeting the global market. 16 April 2025
Biotechnology
US biotech Myeloid Therapeutics has restructured its operations to concentrate on two cancer programs already in the clinic, a move that has resulted in staff reductions and an uncertain future for its early-stage research work. 16 April 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze